Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - magnesium sulfate heptahydrate, quantity: 493 mg/ml - injection, concentrated - excipient ingredients: water for injections - indication as at 8 january 2004: parenteral administration of magnesium is indicated in the treatment of acute hypomagnesaemia. magnesium salts are also indicated to prevent hypomagnesaemia in patients receiving total parenteral nutrition. magnesium sulfate is also indicated in the prevention and treatment of life threatening seizures in the treatment of toxemias of pregnancy (pre-eclampsia and eclampsia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - papaverine hydrochloride, quantity: 12 mg/ml - injection, solution - excipient ingredients: water for injections - papaverine hydrochloride injection is indicated for the treatment of erectile dysfunction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - promethazine hydrochloride, quantity: 25 mg/ml - injection, solution - excipient ingredients: disodium edetate; sodium metabisulfite; glacial acetic acid; sodium acetate; water for injections - indication as 8 january 2004: promethazine hydrochloride injection bp is indicated for the following conditions: treatment of allergic reactions such as: uncomplicated allergic conditions of the immediate type, e.g. pruritus, urticaria and angioedema, when oral therapy is impossible or contraindicated. treatment and prevention of vomiting including: motion sickness; drug induced nausea; prevention and control of nausea and vomiting associated with certain types of anaesthesia and surgery, such as procedures with a high incidence of post-operative vomiting (e.g. gynaecological surgery, strabismus or middle ear surgery, and electroconvulsive therapy); in patients with a past history of motion sickness or post-operative vomiting; and in patients in whom avoidance of vomiting is crucial (e.g. neurosurgery and eye surgery). promethazine has sedative effects and it is also used in: pre-operative, post-operative and obstetric (during labour) sedation.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - isoprenaline hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - isoprenaline hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - chloramphenicol -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - potassium chloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - alprostadil, quantity: 500 microgram/ml - injection, solution - excipient ingredients: ethanol - indications as at 14 january 1994: prostin vr sterile solution (alprostadil) is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon a patent ductus for survival. such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of fallot, interruption of the aortic arch, coarctation of the aorta, mitral atresia, or transposition of the great vessels with or without other defects. prostin vr should be administered only by medically trained personnel in facilities in which paediatric patients can receive or have access to paediatric intensive care.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dantrolene sodium hemiheptahydrate, quantity: 50 mg - capsule - excipient ingredients: sodium lauryl sulfate; maize starch; lactose monohydrate; titanium dioxide; sunset yellow fcf; gelatin; iron oxide yellow; iron oxide red; magnesium stearate; purified talc; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - dantrium is indicated in controlling the manifestations of clinical spasticity resulting from serious chronic disorders such as spinal cord injury, stroke, cerebral palsy, or multiple sclerosis. it is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. there is no evidence that patients with contractures will benefit. dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders or electroconvulsive therapy. if improvement occurs, it will ordinarily occur within the dosage titration schedule (see dosage and administration), as manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without dantrium. occasionally, subtle but meaningful improvements in spasticity may occur with dantrium therapy. in such instances informat

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dantrolene sodium hemiheptahydrate, quantity: 25 mg - capsule - excipient ingredients: titanium dioxide; sunset yellow fcf; purified talc; gelatin; iron oxide red; magnesium stearate; maize starch; sodium lauryl sulfate; lactose monohydrate; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; simethicone - dantrium is indicated in controlling the manifestations of clinical spasticity resulting from serious chronic disorders such as spinal cord injury, stroke, cerebral palsy, or multiple sclerosis. it is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. there is no evidence that patients with contractures will benefit. dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders or electroconvulsive therapy. if improvement occurs, it will ordinarily occur within the dosage titration schedule (see dosage and administration), as manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without dantrium. occasionally, subtle but meaningful improvements in spasticity may occur with dantrium therapy. in such instances inf